So sad to see stories like this... Preeclampsia is a serious and growing concern in maternal health, as highlighted in this wsj article. Despite its rapidly increasing prevalence and death rate, we still have little understanding and lack effective treatments for this life-threatening condition. At Savran Technologies Inc., we're developing a novel screening assay for accurate prediction and early detection of preeclampsia. Early detection is crucial for timely monitoring and intervention, which can greatly improve outcomes for both mothers and babies. With our technology, we hope to help those affected, and transform how we study and understand preeclampsia. This critical area needs more attention and innovation from across the healthcare field. #Preeclampsia #MaternalHealth #WomensHealth #Diagnostics
关于我们
We are biotech company located in the Boston area, with a mission to revolutionize non-invasive diagnostics. The systems we are developing allow monitoring cancer patients' progress, as well as looking very early into pregnancy to gain a complete genetic picture of the fetus, all with a simple blood test.
- 网站
-
https://savrantech.com
Savran Technologies Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Newton，Massachusetts
- 类型
- 私人持股
- 创立
- 2018
- 领域
- Liquid biopsy、Oncology、Prenatal diagnostics和Medical devices
地点
-
主要
获取路线
90 Bridge St
US，Massachusetts，Newton，02458
Savran Technologies Inc.员工
-
?a?r? Savran
Founder & CEO at Savran Technologies Inc.
-
Nadia F. Altomare
Vice President, President & Chief Commercial Officer (CCO) | Life Sciences | Diagnostics | Biotechnology
-
Yuan Zhong
Advanced Engineer | Non-invasive diagnostics via rare cell isolation
-
Chun-Li Chang
Director of R&D at Savran Technologies Inc.,